Pfizer Stock Rises as Drug Giant Sees 2025 Revenue of $61 Billion to $64 Billion -- Barrons.com

Dow Jones12-17

By Josh Nathan-Kazis

Shares of Pfizer were rising in premarket trading Tuesday after the drug company released financial guidance for 2025 that roughly lined up with Wall Street expectations.

Pfizer said it expects revenue of between $61 billion and $64 billion next year, in line with the current $63.2 billion FactSet consensus estimate.

The company said it anticipates adjusted earnings of between $2.80 and $3 a share in 2025. Analysts had been expecting adjusted earnings of $2.86.

Sales of Pfizer's Covid-19 products will be roughly similar in 2025 to 2024, the company said, with the exception of $1.2 billion in non-recurring revenue tied to government purchases of the Covid-19 antiviral Paxlovid this year.

Pfizer shares came into Tuesday down 12% for the year.

The company has been working through numerous cost-cutting programs. Pfizer said those remained on track, and that it would see an additional $500 million in savings in 2025.

"Pfizer is in a strong position to continue making a positive impact for patients and delivering on our financial commitments in 2025," CEO Albert Bourla said in a statement. "Our team will build on a year of disciplined execution in 2024 and our product portfolio remains strong."

Write to Josh Nathan-Kazis at josh.nathan-kazis@barrons.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

December 17, 2024 07:20 ET (12:20 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492956738?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-17 20:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492956738","market":"fut","top_or_hot":-1,"title":"Pfizer Stock Rises as Drug Giant Sees 2025 Revenue of $61 Billion to $64 Billion -- Barrons.com","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Josh Nathan-Kazis \n</p>\n<p>\n  Shares of Pfizer were rising in premarket trading Tuesday after the drug company released financial guidance for 2025 that roughly lined up with Wall Street expectations. \n</p>\n<p>\n     Pfizer said it expects revenue of between $61 billion and $64 billion next year, in line with the current $63.2 billion FactSet consensus estimate. \n</p>\n<p>\n     The company said it anticipates adjusted earnings of between $2.80 and $3 a share in 2025. Analysts had been expecting adjusted earnings of $2.86. \n</p>\n<p>\n     Sales of Pfizer's Covid-19 products will be roughly similar in 2025 to 2024, the company said, with the exception of $1.2 billion in non-recurring revenue tied to government purchases of the Covid-19 antiviral Paxlovid this year. \n</p>\n<p>\n     Pfizer shares came into Tuesday down 12% for the year. \n</p>\n<p>\n     The company has been working through numerous cost-cutting programs. Pfizer said those remained on track, and that it would see an additional $500 million in savings in 2025. \n</p>\n<p>\n     \"Pfizer is in a strong position to continue making a positive impact for patients and delivering on our financial commitments in 2025,\" CEO Albert Bourla said in a statement. \"Our team will build on a year of disciplined execution in 2024 and our product portfolio remains strong.\" \n</p>\n<p>\n     Write to Josh Nathan-Kazis at  josh.nathan-kazis@barrons.com \n</p>\n<p>\n     This content was created by Barron's, which is operated by Dow Jones &amp; Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 17, 2024 07:20 ET (12:20 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Stock Rises as Drug Giant Sees 2025 Revenue of $61 Billion to $64 Billion -- Barrons.com</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Stock Rises as Drug Giant Sees 2025 Revenue of $61 Billion to $64 Billion -- Barrons.com\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-17 20:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Josh Nathan-Kazis \n\n\n  Shares of Pfizer were rising in premarket trading Tuesday after the drug company released financial guidance for 2025 that roughly lined up with Wall Street expectations. \n\n\n...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PFE","symbol_name":"辉瑞","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2492956738","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492956738","pubTimestamp":1734438000,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Pfizer were rising in premarket trading Tuesday after the drug company released financial guidance for 2025 that roughly lined up with Wall Street expectations.Pfizer said it expects revenue of between $61 billion and $64 billion next year, in line with the current $63.2 billion FactSet consensus estimate.The company said it anticipates adjusted earnings of between $2.80 and $3 a share in 2025. Analysts had been expecting adjusted earnings of $2.86.Sales of Pfizer's Covid-19 products will be roughly similar in 2025 to 2024, the company said, with the exception of $1.2 billion in non-recurring revenue tied to government purchases of the Covid-19 antiviral Paxlovid this year.Pfizer shares came into Tuesday down 12% for the year.The company has been working through numerous cost-cutting programs. Pfizer said those remained on track, and that it would see an additional $500 million in savings in 2025.\"Pfizer is in a strong position to continue making a positive impact for patient","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"PFE":"辉瑞"},"translate_title":"制药巨头辉瑞预计2025年收入将达到610亿美元至640亿美元，股价上涨--Barrons.com","themeId":"82d36a84b850c4ce90d704ad5a74f9ba","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":1},"content_text":"By Josh Nathan-Kazis \n\n\n  Shares of Pfizer were rising in premarket trading Tuesday after the drug company released financial guidance for 2025 that roughly lined up with Wall Street expectations. \n\n\n     Pfizer said it expects revenue of between $61 billion and $64 billion next year, in line with the current $63.2 billion FactSet consensus estimate. \n\n\n     The company said it anticipates adjusted earnings of between $2.80 and $3 a share in 2025. Analysts had been expecting adjusted earnings of $2.86. \n\n\n     Sales of Pfizer's Covid-19 products will be roughly similar in 2025 to 2024, the company said, with the exception of $1.2 billion in non-recurring revenue tied to government purchases of the Covid-19 antiviral Paxlovid this year. \n\n\n     Pfizer shares came into Tuesday down 12% for the year. \n\n\n     The company has been working through numerous cost-cutting programs. Pfizer said those remained on track, and that it would see an additional $500 million in savings in 2025. \n\n\n     \"Pfizer is in a strong position to continue making a positive impact for patients and delivering on our financial commitments in 2025,\" CEO Albert Bourla said in a statement. \"Our team will build on a year of disciplined execution in 2024 and our product portfolio remains strong.\" \n\n\n     Write to Josh Nathan-Kazis at  josh.nathan-kazis@barrons.com \n\n\n     This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 17, 2024 07:20 ET (12:20 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492956738"}